Literature DB >> 4130196

[Cellular immune response to hepatitis-associated antigen and homologous liver-specific protein in acute HAA-positive hepatitis (author's transl)].

J Knolle, J P Bolte, J Berger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4130196     DOI： 10.1007/bf01468568

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


× No keyword cloud information.
  12 in total

1.  A "NEW" ANTIGEN IN LEUKEMIA SERA.

Authors:  B S BLUMBERG; H J ALTER; S VISNICH
Journal:  JAMA       Date:  1965-02-15       Impact factor: 56.272

Review 2.  [Immunopathogenesis of chronic inflammatory liver diseases].

Authors: 
Journal:  Ergeb Inn Med Kinderheilkd       Date:  1972

3.  A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis.

Authors:  B S Blumberg; B J Gerstley; D A Hungerford; W T London; A I Sutnick
Journal:  Ann Intern Med       Date:  1967-05       Impact factor: 25.391

4.  Association of autoimmune active chronic hepatitis with HL-A1,8.

Authors:  I R Mackay; P J Morris
Journal:  Lancet       Date:  1972-10-14       Impact factor: 79.321

5.  Hepatitis-associated (Au-SH) antigen determination in 10,000 patients in a Copenhagen general hospital.

Authors:  P Lous; H Olesen; P Skinhoj
Journal:  Lancet       Date:  1970-07-18       Impact factor: 79.321

6.  [Cellular immune reactions towards homologous liver-specific antigens (HLP) in chronic inflammatory liver diseases (author's transl)].

Authors:  K H von Meyer zum Büschenfelde; J Knolle; J Berger
Journal:  Klin Wochenschr       Date:  1974-03-01

7.  Chronic hepatitis--migration inhibition of leukocytes in the presence of Australia antigen.

Authors:  K Ito; J Nakagawa; Y Okimoto; H Nakano
Journal:  N Engl J Med       Date:  1972-05-04       Impact factor: 91.245

8.  Liver specific antigens. Purification and characterization.

Authors:  P A Miescher
Journal:  Clin Exp Immunol       Date:  1972-01       Impact factor: 4.330

9.  Australia antigen and hepatitis. Studies in asymptomatic people and lepromatous leprosy patient.

Authors:  B S Blumberg; L Melartin
Journal:  Arch Intern Med       Date:  1970-02

10.  [In vitro studies on the influence of the migration inhibition factor (MIF) of lymphocytes on peripheral blood monocytes and granulocytes in man].

Authors:  C P Sodomann; M Schmidt; K Havemann
Journal:  Verh Dtsch Ges Inn Med       Date:  1971
View more
  6 in total

1.  [Aggressive emperipolesis in chronic hepatitis (author's transl)].

Authors:  H Bechtelsheimer; P Gedgik; R Müller; H Klein
Journal:  Klin Wochenschr       Date:  1976-02-01

2.  Organ-specificity and diagnostic value of cell-mediated immunity against a liver-specific membrane protein: studies in hepatic and non-hepatic diseases.

Authors:  K H Meyer zum Büschenfelde; A Alberti; W Arnold; J Freudenberg
Journal:  Klin Wochenschr       Date:  1975-11-15

3.  Leucocyte migration inhibition with inner and outer membranes of mitochondria and insoluble hepatocyte surface membranes prepared from rat liver in patients with chronic hepatitis and cirrhosis.

Authors:  G Ohta; A Nonomura; I Nishimura
Journal:  Clin Exp Immunol       Date:  1976-12       Impact factor: 4.330

4.  [Investigations concerning the fixation of hepatitis B-antigen (HBAg) on peripheral lymphocytes and isolated hepatocytes in patients with inflammatory liver diseases. (author's transl)].

Authors:  W Arnold; K H Meyer zum Büschenfelde; U Hopf; C Kordbarlag
Journal:  Klin Wochenschr       Date:  1975-03-01

5.  LM-Ag and LSP--two different target antigens involved in the immunopathogenesis of chronic active hepatitis?

Authors:  K H Meyer zum Büschenfelde; M Manns; T H Hütteroth; U Hopf; W Arnold
Journal:  Clin Exp Immunol       Date:  1979-08       Impact factor: 4.330

6.  Fractionation of the liver membrane lipoprotein (LSP) and characterisation of its antigenic determinants by autoantibodies and a heterologous anti-serum.

Authors:  M Manns; K H Meyer zum Büschenfelde
Journal:  Gut       Date:  1982-01       Impact factor: 23.059
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.